Lifecore Biomedical Q1 EPS $(0.53) Misses $(0.49) Estimate, Sales $24.70M Beat $23.19M Estimate
Portfolio Pulse from Benzinga Newsdesk
Lifecore Biomedical reported a Q1 EPS loss of $(0.53), missing the $(0.49) estimate, but sales of $24.70M beat the $23.19M estimate. EPS decreased by 29.27% from last year, while sales increased by 0.75%.
October 04, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Lifecore Biomedical's Q1 EPS of $(0.53) missed estimates, showing a significant decline from last year, but sales exceeded expectations. This mixed result may lead to short-term stock volatility.
The missed EPS estimate indicates a negative performance compared to expectations, which could pressure the stock price. However, the sales beat provides a positive aspect, potentially offsetting some negative sentiment. The mixed results suggest potential volatility in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100